Healthcare Business Recap: Amgen’s Limitation, Sanofi’s Earnings
Sanofi’s (NYSE:SNY) fourth quarter income of Genzyme and emerging markets offsets the death of patents and the effect of European Union rigor. Sanofi’s earnings per share will fall 12%-15% due to patent loss of Plavix and Avapro, but predicts 5% annual sales growth and faster earnings per share growth after that to 2015.
Investing Insights: Neurocrine Biosciences Inc. Earnings: Weak Revenue and Net Income.
GlaxoSmithKline (NYSE:GSK) says it’s been deporting large sums of cash out of eurozone countries for months, converting euros back daily to the United Kingdom in sterling, out of fear the debt crisis may take a turn for the worse. “You don’t have money in banks you’re nervous about,” CEO Sir Andrew Witty remarked at the company’s annual presentation in London.
Amgen’s (NASDAQ:AMGN) Xgeva, which is used for prostate cancer bone metastasis prevention, according to a Bloomberg report, has been limited in use by a 12-1 vote from the Food and Drug Administration.
Johnson & Johnson (NYSE:JNJ), Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), AstraZeneca Plc. (NYSE:AZN) and Eisai Co., Ltd. (ESALY.PK) are amongst the big pharmaceutical companies that produce stomach-acid medications the Food and Drug Administration warns can cause a dangerous bacterial infection. Numerours drugs include the at-risk PPI medication with Protonix, AcipHex, and Nexium being some of the larger names.
Cerner’s (NASDAQ:CERN) strong fourth quarter is providing assistance to other healthcare IT names. Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX), Merge Healthcare, Inc. (NASDAQ:MRGE), Computer Programs & Systems, Inc. (NASDAQ:CPSI), and Quality Systems, Inc. (NASDAQ:QSII) are all going up meanwhile, and they might also be getting a boost from a UBS, Inc. (NYSE:UBS) note claiming management struck a bullish tone at a recent conference.
To contact the reporter on this story: at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com